OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+22.31%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$511M
AUM Growth
+$511M
(+3.3%)
Cap. Flow
+$46.3M
Cap. Flow
% of AUM
9.05%
Top 10 Holdings %
Top 10 Hldgs %
48.76%
Holding
68
New
20
Increased
11
Reduced
12
Closed
13
Top Buys
| 1 |
AFIB
Acutus Medical, Inc. Common Stock
AFIB
|
$22.4M |
| 2 |
Cardiff Oncology
CRDF
|
$16.2M |
| 3 |
Vaxcyte
PCVX
|
$15.5M |
| 4 |
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
|
$10.4M |
| 5 |
Seres Therapeutics
MCRB
|
$9.49M |
Top Sells
| 1 |
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
|
$10.6M |
| 2 |
uniQure
QURE
|
$8.55M |
| 3 |
APTO
Aptose Biosciences, Inc.
APTO
|
$7.99M |
| 4 |
MTEM
Molecular Templates, Inc.
MTEM
|
$6.83M |
| 5 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$6.55M |
Sector Composition
| 1 | Healthcare | 92.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ocular Therapeutix
OCUL
$2.12B
| $45.5M | 8.91% | 5,984,200 | – | – |
|
2
Protara Therapeutics
TARA
$120M
| $43.1M | 8.42% | 2,558,472 +350,000 | +16% | +$5.89M |
|
3
Eton Pharmaceutcials
ETON
$464M
| $28.8M | 5.62% | 3,640,000 | – | – |
|
|
4
Cardiff Oncology
CRDF
$140M
| $24.6M | 4.81% | 1,731,600 +1,141,600 | +193% | +$16.2M |
|
|
AFIB
5
DELISTED
Acutus Medical, Inc. Common Stock
AFIB
| $22.4M | 4.37% | +749,990 | New | +$22.4M |
|
|
CCXI
6
DELISTED
ChemoCentryx, Inc.
CCXI
| $19.5M | 3.82% | 356,000 -5,600 | -2% | -$307K |
|
7
Neurogene
NGNE
$264M
| $16.6M | 3.25% | 1,386,300 -13,700 | -1% | -$164K |
|
8
Harrow
HROW
$1.44B
| $16.5M | 3.24% | 2,959,000 +249,000 | +9% | +$1.39M |
|
9
Codexis
CDXS
$246M
| $16.4M | 3.21% | 1,400,000 | – | – |
|
|
EIDX
10
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $15.9M | 3.12% | 315,550 | – | – |
|
|
11
Vaxcyte
PCVX
$4B
| $15.5M | 3.02% | +313,000 | New | +$15.5M |
|
12
Celldex Therapeutics
CLDX
$1.47B
| $14.7M | 2.88% | 992,000 -79,000 | -7% | -$1.17M |
|
13
MacroGenics
MGNX
$112M
| $13.3M | 2.6% | 527,000 +26,000 | +5% | +$655K |
|
|
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $11.4M | 2.23% | 222,000 | – | – |
|
15
Stereotaxis
STXS
$261M
| $10.8M | 2.12% | 3,021,436 -490,064 | -14% | -$1.75M |
|
|
APTO
16
DELISTED
Aptose Biosciences, Inc.
APTO
| $10.8M | 2.11% | 1,799,000 -1,331,000 | -43% | -$7.99M |
|
|
ATXI
17
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
| $10.7M | 2.09% | 984,692 -50,308 | -5% | -$545K |
|
18
TG Therapeutics
TGTX
$4.65B
| $10.4M | 2.04% | 390,000 -66,600 | -15% | -$1.78M |
|
|
TCON
19
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $10.4M | 2.04% | +2,013,438 | New | +$10.4M |
|
20
Fortress Biotech
FBIO
$76.8M
| $10.3M | 2.01% | 3,830,000 | – | – |
|
|
MYOV
21
DELISTED
Myovant Sciences Ltd.
MYOV
| $9.59M | 1.88% | 682,500 | – | – |
|
|
CMRX
22
DELISTED
Chimerix, Inc.
CMRX
| $9.57M | 1.87% | 3,841,500 +1,736,500 | +82% | +$4.32M |
|
|
23
Seres Therapeutics
MCRB
$166M
| $9.49M | 1.86% | +335,312 | New | +$9.49M |
|
|
SIOX
24
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $9.42M | 1.84% | +2,039,100 | New | +$9.42M |
|
25
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $8.78M | 1.72% | 338,000 -6,500 | -2% | -$169K |
|